2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 Potently Stimulates Gene-specific DNA Binding of the Vitamin D Receptor in Osteoblasts*

2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 (2MD) is a highly potent analog of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) whose actions are mediated through the vitamin D receptor (VDR). In this report, we have replicated this increased potency of 2MD in vitro using osteoblastic cells and explored its underlying molecular mechanism. 2MD stimulates the expression of several vitamin D-sensitive genes including 25-hydroxyvitamin D3-24 hydroxylase (Cyp24), osteopontin and receptor activator of NFκB ligand and suppresses osteoprotegerin at concentrations two logs lower than that for 1,25(OH)2D3. 2MD is also more potent in stimulating transfected chimeric reporter genes under either Cyp24 or the osteocalcin promoter control. Enhanced potency is retained regardless of medium serum content. Interestingly, the uptake of both 1,25(OH)2D3 and 2MD into cells is similar, as is their rapid association with the VDR. This indicates that comparable levels of occupied VDR do not elicit equivalent levels of transactivation. Using chromatin immunoprecipitation (ChIP), however, we observed a strong correlation between DNA-bound receptor and the level of induced transcription suggesting a 2MD-induced increase in affinity of the VDR for DNA. Additional studies using a mammalian two-hybrid system and ChIP indicate that 2MD is also more potent in promoting interaction with RXR and the coactivators SRC-1 and DRIP205. Finally, protease digestion studies revealed a unique VDR conformation in the presence of 2MD. These studies suggest that the molecular mechanism of 2MD potency is due to its ability to promote enhanced levels of specific DNA binding by the VDR and could suggest possible explanations for the tissue- and gene-selective actions of 2MD.

[1]  S. Peleg,et al.  2α-(3-Hydroxypropyl)- and 2α-(3-Hydroxypropoxy)-1α,25-dihydroxyvitamin D3 Accessible to Vitamin D Receptor Mutant Related to Hereditary Vitamin D-Resistant Rickets , 2003 .

[2]  N. Kubodera,et al.  A new active vitamin D analog, ED‐71, causes increase in bone mass with preferential effects on bone in osteoporotic patients , 2003, Journal of cellular biochemistry.

[3]  C. Carlberg Molecular basis of the selective activity of vitamin D analogues , 2003, Journal of cellular biochemistry.

[4]  J. Pike,et al.  Inhibition of 1,25‐Dihydroxyvitamin D3‐Dependent Transcription by Synthetic LXXLL Peptide Antagonists that Target the Activation Domains of the Vitamin D and Retinoid X Receptors , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  G. Buchanan,et al.  A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. , 2002, Molecular endocrinology.

[6]  H. DeLuca,et al.  A potent analog of 1α,25-dihydroxyvitamin D3 selectively induces bone formation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Der,et al.  Role of MAP Kinases in the 1,25-Dihydroxyvitamin D3-induced Transactivation of the Rat Cytochrome P450C24 (CYP24) Promoter , 2002, The Journal of Biological Chemistry.

[8]  J. Pike,et al.  Vitamin D receptor-mediated gene regulation mechanisms and current concepts of vitamin D analog selectivity. , 2002, Advances in renal replacement therapy.

[9]  P. Farnham,et al.  Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. , 2002, Methods.

[10]  M. Galligan,et al.  Distinct retinoid X receptor activation function-2 residues mediate transactivation in homodimeric and vitamin D receptor heterodimeric contexts. , 2001, Journal of molecular endocrinology.

[11]  D. Moras,et al.  Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.

[13]  M Carlquist,et al.  Structural aspects of agonism and antagonism in the oestrogen receptor. , 2000, Biochemical Society transactions.

[14]  J. Pike,et al.  Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Carlberg,et al.  Response element and coactivator-mediated conformational change of the vitamin D(3) receptor permits sensitive interaction with agonists. , 2000, Molecular pharmacology.

[16]  Alex J. Brown,et al.  Mechanisms for the selective actions of vitamin D analogues. , 2000, Current pharmaceutical design.

[17]  B. O’Malley,et al.  Phosphorylation of Steroid Receptor Coactivator-1 , 2000, The Journal of Biological Chemistry.

[18]  Sundeep Khosla,et al.  The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  D. Fowlkes,et al.  Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β , 1999, Molecular and Cellular Biology.

[20]  S. Morony,et al.  A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL‐1β, TNF‐α, PTH, PTHrP, and 1,25(OH)2D3 , 1999 .

[21]  L. Freedman,et al.  20-Epi Analogues of 1,25-Dihydroxyvitamin D3 Are Highly Potent Inducers of DRIP Coactivator Complex Binding to the Vitamin D3 Receptor* , 1999, The Journal of Biological Chemistry.

[22]  R. K. DeLisle,et al.  The Autonomous Transactivation Domain in Helix H3 of the Vitamin D Receptor Is Required For Transactivation and Coactivator Interaction* , 1999, The Journal of Biological Chemistry.

[23]  P. Mäenpää,et al.  Structure-function studies of new C-20 epimer pairs of vitamin D3 analogs. , 1999, European journal of biochemistry.

[24]  B. O’Malley,et al.  Proteasome-dependent degradation of the human estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[26]  H. Masuyama,et al.  Proteasome‐mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF‐2 domain of VDR , 1998, Journal of cellular biochemistry.

[27]  H. DeLuca,et al.  New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. , 1998, Journal of medicinal chemistry.

[28]  H. DeLuca,et al.  Current understanding of the molecular actions of vitamin D. , 1998, Physiological reviews.

[29]  M. Haussler,et al.  The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  R. Baron,et al.  Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Elgort,et al.  Retinoid X Receptor (RXR) Ligands Activate the Human 25-Hydroxyvitamin D3-24-hydroxylase Promoter via RXR Heterodimer Binding to Two Vitamin D-responsive Elements and Elicit Additive Effects with 1,25-Dihydroxyvitamin D3 * , 1997, The Journal of Biological Chemistry.

[32]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.

[33]  L. Binderup,et al.  Development of new vitamin D analogs , 1997 .

[34]  A. Norman,et al.  Distinct Conformational Changes Induced by 20-epi Analogues of 1,25-Dihydroxyvitamin D Are Associated with Enhanced Activation of the Vitamin D Receptor (*) , 1995, The Journal of Biological Chemistry.

[35]  D. Bikle Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. , 1992, Endocrine reviews.

[36]  D. Edwards,et al.  Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. , 1992, The Journal of biological chemistry.

[37]  J. Pike,et al.  Vitamin D receptor interaction with specific DNA. Association as a 1,25-dihydroxyvitamin D3-modulated heterodimer. , 1991, The Journal of biological chemistry.

[38]  L. Binderup,et al.  Calcipotriol (MC 903): pharmacokinetics in rats and biological activities of metabolites. A comparative study with 1,25(OH)2D3. , 1991, Biochemical pharmacology.

[39]  K. Ozono,et al.  The vitamin D-responsive element in the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer. , 1990, The Journal of biological chemistry.

[40]  J. Haddad,et al.  Vitamin D binding protein (Gc-globulin). , 1989, Endocrine reviews.

[41]  B. O’Malley,et al.  Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. , 1988, Science.

[42]  M. Haussler,et al.  Association of 1,25-dihydroxyvitamin D3 with cultured 3T6 mouse fibroblasts. Cellular uptake and receptor-mediated migration to the nucleus. , 1983, The Journal of biological chemistry.

[43]  M. Haussler,et al.  Serum and monoclonal antibodies against the chick intestinal receptor for 1,25-dihydroxyvitamin D3. Generation by a preparation enriched in a 64,000-dalton protein. , 1983, The Journal of biological chemistry.

[44]  P. Holland,et al.  Inactivation of pig heart thiolase by 3-butynoyl coenzyme A, 3-pentynoyl coenzyme A, and 4-bromocrotonyl coenzyme A. , 1973, Biochemistry.

[45]  D. Moras,et al.  The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. , 2000, Molecular cell.

[46]  H. DeLuca,et al.  Modern view of vitamin D3 and its medicinal uses. , 1998, Progress in medicinal chemistry.